<DOC>
	<DOCNO>NCT00868439</DOCNO>
	<brief_summary>The purpose study assess effect patiromer serum potassium participant heart failure . This study also assess safety tolerability patiromer participant heart failure .</brief_summary>
	<brief_title>Evaluation Patiromer Heart Failure Patients</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , parallel-group , multiple-dose study congestive heart failure participant . Depending outcome initial cohort 100 participant ( Part 1 ) , second cohort 170 participant could enrol ( Part 2 ) . Based result Part 1 study , Part 2 conduct . Participants randomly assign receive patiromer ( 30 g/day ) placebo 28 day . All participant also receive spironolactone ; initial spironolactone dose 25 mg daily increase 50 mg daily participant serum potassium â‰¤ 5.1 mEq/L treatment Day 14 . Study visit occur treatment Days 3 , 7 , 14 , 17 , 21 28 . A safety follow-up contact make 7 day administration last dose study drug .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>Participants chronic heart failure clinically indicate receive spironolactone therapy , age 18 year old serum potassium level 4.3 5.1 mEq/L screen baseline , AND ( 1 ) chronic kidney disease ( GFR &lt; 60 mL/min ) OR ( 2 ) document history hyperkalemia within last 6 month Females childbearing potential must nonlactating , must negative serum pregnancy test screening , must use highly effective form contraception least 3 month study drug administration , study , one month study completion Male participant and/or female partner childbearing potential must use highly effective form contraception study 3 month study completion Must sign inform consent document History bowel obstruction , swallow disorder , severe gastrointestinal disorder major gastrointestinal surgery Uncorrected hemodynamically significant primary valvular disease , know obstructive restrictive cardiomyopathy , uncontrolled hemodynamically unstable arrhythmia Coronaryartery bypass graft , percutaneous intervention ( e.g . cardiac , cerebrovascular , aortic ) , major surgery include thoracic cardiac , within 3 month prior baseline anticipate need study participation Heart transplant recipient , anticipate need transplant study participation Any follow event occur within 3 month prior baseline : unstable angina judge Investigator , unresolved acute coronary syndrome , transient ischemic attack stroke Current dialysis participant , anticipate need dialysis study participation Prior kidney transplant , anticipate need transplant study participation Metastatic , latestage endstage cancer &lt; 12 month life expectancy History alcoholism drug/chemical abuse within 1 year QTcB interval &gt; 500 msec ( Bazett 's correction formula ) Sustained systolic blood pressure &gt; 170 &lt; 90 mmHg Liver enzymes ( ALT , AST ) &gt; 3 time upper limit normal Use oral cardiac medication ( include loop thiazide diuretic ) stable least 21 day prior baseline anticipate remain stable study participation Use IV cardiac medication within 21 day prior baseline , anticipate need study participation . Current use polymerbased drug ( e.g . Renagel , Kayexalate , Welchol , Colestid ) , phosphate binder potassium binder , calcium supplement , antacid ( eg TUMS , Maalox ) , anticipate need study participation Use aldosterone antagonist last 30 day prior baseline , unless discontinue due hyperkalemia Use potassium spar medication and/or potassium supplement last 30 day prior baseline Use investigational medication , 30 day 5 halflives whichever longer , prior baseline Participants take investigational product study , previous patiromer study Inability consume study medication , , opinion Investigator , inability comply protocol In opinion Investigator , medical condition , uncontrolled systemic disease , serious intercurrent illness , extenuate circumstance occur persisting , within 30 day prior baseline , would significantly decrease study compliance jeopardize safety participant affect validity trial result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HF</keyword>
	<keyword>Heart failure</keyword>
	<keyword>hyperkalemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>prevention hyperkalemia heart failure participant</keyword>
</DOC>